With there being a lack of in vitro cell models for FUS+MB-mediated drug permeability screening, we tested our established APOE3 and APOE4 iBEC platform for FUS+MB-mediated AD antibody delivery using a similar approach to our previously published study 18. Here, APOE is linked to Alzheimer disease.